Pharmacological action
Selective estrogen receptor modulator. Acts as an agonist on tissues of the body not associated with reproduction, and as an antagonist on reproductive tissues. The action is due to high-affinity binding to estrogen receptors and regulation of gene expression.
Reduces the process of bone resorption and normalizes the calcium balance in the body, primarily by reducing calcium loss in the urine.
Does not cause proliferation of the endometrium, an increase in the size of the uterus, bloody discharge or bleeding in the postmenopausal period. No cases of de novo endometrial cancer have been described. Does not cause hyperplasia of breast tissue. Reduces swelling and soreness of the mammary glands.
Reduces the levels of total cholesterol and LDL. The level of HDL and triglycerides does not change significantly. Reduces the content of fibrinogen in blood plasma.
Indications for the active ingredients of Evista
Prevention of osteoporosis in postmenopausal women.
Dosage regimen
The method of administration and dosage regimen of a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly observe the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.
Contraindications for use
Thromboembolism, including deep vein thrombosis, pulmonary embolism and retinal vein thrombosis, liver disease (including cholestasis), severe renal dysfunction, uterine bleeding of unknown etiology, breast cancer, endometrial cancer, hypersensitivity to raloxifene.
Warning: always consult a doctor before using medications.
